Loading stock data…
Lexaria Bioscience Corp. (LEXX)
$9.37-4.78 (-33.78%)
After Hours$9.82+0.45 (+4.80%)· Last close Sep 8
Lexaria Bioscience Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lexaria Bioscience Corp. in the Healthcare sector is trading at $9.37 with a market capitalization of $15M. Wall Street consensus targets $52.50 (2 analysts), implying a +460.3% move over the next 12 months. The stock is currently 60% below its 52-week high of $23.25, remaining 13.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +460.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $20,000 | $0↓ | $174,000 | $174,000 |
| Gross Profit | $0↓ | $20,000 | $0↓ | $174,000 | $174,000 |
| Operating Income | -$1.99M↓ | -$1.45M↑ | -$1.57M↑ | -$2.69M↑ | -$3.75M |
| Net Income | -$1.99M↓ | -$1.45M↑ | -$1.60M↑ | -$2.70M↑ | -$3.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich tr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-163.18%
Volume
Today's trading volume
121,237
Recent News
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Lexaria releases additional results from Phase 1b study GLP-1-H24-4
Lexaria Bioscience (LEXX) provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH study arms relative to the Rybelsus control study arm. At week 16, rough parity was reached between the DHT arms and the Rybelsus control as there were no statistically significant treatment differences observed in terms of the numerical least squares means changes from ba
Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Lexaria Bioscience Corp.'s ( NASDAQ:LEXX ) business as it appears the...